Immuno-Oncology

Eric Vallieres, MD, FRCSC, discussed recent advancements in surgical oncology regarding the treatment of patients with non–small cell lung cancer (NSCLC)

Toripalimab in combination with etoposide and platinum has been approved by the NMPA in China in first-line extensive-stage small cell lung cancer.

The FDA has approved pembrolizumab plus carboplatin and paclitaxel, followed by pembrolizumab alone, for primary advanced or recurrent endometrial carcinoma.

The FDA had approved durvalumab plus, followed by single-agent durvalumab, for dMMR primary advanced or recurrent endometrial cancer.

Eric Vallieres, MD, FRCSC, discusses the evolving role of surgery in lung cancer treatment following the implementation of new neoadjuvant and adjuvant treatments.

Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma

In a phase 2 trial, all 42 patients with locally advanced mismatch repair–deficient rectal cancer achieved clinical complete response with dostarlimab.

Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.

Pembrolizumab plus sacituzumab govitecan numerically improved PFS vs the ADC alone in HR-positive, HER2-negative metastatic breast cancer.

Consolidation treatment with durvalumab after concurrent chemoradiation led to a survival benefit vs placebo in limited-stage small cell lung cancer.

Neoadjuvant nivolumab/ipilimumab followed by TLND and response-driven adjuvant therapy reduced the risk of progression, recurrence, or death in melanoma.

Induction encorafenib/binimetinib before nivolumab/ipilimumab did not improve PFS in unresectable or metastatic BRAF V600E/K–positive melanoma.

Adding atezolizumab to neoadjuvant pertuzumab, trastuzumab, and chemotherapy produced improved EFS and DFS rates in HER2-positive early breast cancer.

The European Commission approved nivolumab plus cisplatin and gemcitabine for first-line treatment in unresectable or metastatic urothelial carcinoma.

Thomas F. Gajewski, MD, PhD, discusses the mechanism through which the gut microbiome modulates myeloid cells to regulate responses to immunotherapy.

Michelle Krogsgaard, PhD, discusses the identification and potentially utility of phosphorylated neoantigen targets for anticancer vaccine development.

The FDA has updated the PDUFA target action date for the BLA for subcutaneous nivolumab in advanced or metastatic solid tumors.

Jameel Muzaffar, MD, discusses findings from the phase 2 portion of the FLX475-02 study examining tivumecirnon plus pembrolizumab in HNSCC.

Jorge J. Nieva, MD, details the benefits of telemedicine and a first-of-its-kind clinical trial where patients with NSCLC will receive subcutaneous immunotherapy at home.

Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.

Relatlimab plus nivolumab and chemotherapy did not improve responses in untreated advanced gastric or GEJ cancer with a LAG-3 expression of at least 1%.

Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.

First-line treatment with the combination of Versamune HPV and pembrolizumab met a best overall response end point in recurrent/metastatic HNSCC.

Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.

Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.